Vitamin D for Post-Illness Recovery

Illness lowers vitamin D, and low vitamin D looks like poor recovery - which makes this one of the easiest places in nutrition to mistake a consequence for a cause.

Acute inflammation reduces circulating 25-hydroxyvitamin D independently of stores, so a low reading taken during or shortly after illness often reflects the illness rather than a deficiency that caused it. Observational studies linking low vitamin D to worse outcomes are heavily confounded by this, as well as by indoor confinement, obesity and general ill health. That said, correcting genuine deficiency is worthwhile. Meta-analyses of randomised trials show that regular daily vitamin D modestly reduces acute respiratory infection risk, with the benefit concentrated in people who were deficient at baseline, and deficiency contributes independently to muscle weakness and fatigue during convalescence. Large bolus doses have not shown this benefit.

Recovery from illness requires resolution of inflammation, restoration of muscle mass and function, and rebuilding of immune competence. Vitamin D receptors are expressed on most immune cells, and macrophages convert 25-hydroxyvitamin D locally to the active hormone, giving it a direct paracrine role in immune regulation.

Calcitriol induces antimicrobial peptides including cathelicidin and defensins, supports epithelial barrier integrity in the respiratory tract, and shifts adaptive responses towards regulatory T cells, dampening excessive inflammation. In skeletal muscle it supports type II fibre function, which is why deficiency causes proximal weakness and difficulty rising from a chair. What vitamin D cannot address is the dominant driver of post-illness weakness: disuse atrophy and catabolic muscle loss. That responds to protein and progressive loading.

Daily dosing outperforms bolus regimens for immune endpoints.

There are currently no studies linked to this pairing in our library, so no study list is shown.

Individual participant data meta-analyses of randomised trials show a small reduction in acute respiratory infection risk with daily or weekly vitamin D, largest in those with baseline levels below 25 nmol/L. Trials in deficient older adults also show improved muscle strength and reduced falls, both relevant to convalescence. Evidence for recovery specifically is weak. Trials measure infection incidence, falls or biochemical endpoints rather than time to return to normal function, large bolus doses have repeatedly failed and sometimes harmed, and the widely cited observational associations with severe illness outcomes are confounded by reverse causation. No trial has shown that supplementation speeds recovery in replete people.

Vitamin D at 1000-4000 IU daily is safe for most adults. Toxicity is uncommon but real with sustained high intake, producing hypercalcaemia with nausea, thirst, polyuria, confusion and kidney injury.

Avoid high doses in sarcoidosis, tuberculosis and other granulomatous disease, where unregulated activation causes hypercalcaemia, and in primary hyperparathyroidism or calcium stone disease without supervision. Very large intermittent bolus doses have been associated with increased falls and fractures in older adults, and should be avoided.

Calcium handling and dosing pattern are the practical issues.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.